A phase II trial showed that nivolumab plus LAG3 blockade (relatlimab) achieved comparable efficacy to nivolumab plus ipilimumab with improved safety in advanced RCC (76), and two additional trials (NCT05148546 and NCT06708949) are ongoing. The gene discussed is LAG3; the disease is renal cell carcinoma.